tirzepatide/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases glycated haemoglobin (HbA1c)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“All three tirzepatide doses were associated with a significant decrease in HbA1c levels compared to placebo (Figure S8 and Table S3).”
Quoted verbatim from Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.. - Study
- meta-analysis
- Dose
- 5, 10 and 15 mg once weekly
- Population
- Adults with or without type 2 diabetes in placebo-controlled trials, 12 to 72 weeks; all three doses
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.2024PMID:38850440Industry fundedPermalink
Keep reading
- Everything the graph holds on tirzepatide
- Every compound studied against Glycated haemoglobin (HbA1c)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PR6HXSAESTQDD3WZY9CBTJ